Pharvaris
PHVS
33 hedge funds and large institutions have $617M invested in Pharvaris in 2021 Q1 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
69.17% more ownership
Funds ownership: 0% → 69.17% (+69%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$103M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$100M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$87.1M |
| 4 |
GA
General Atlantic
New York
|
+$76.1M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$76.1M |
Top Sellers
PHVS Hedge Fund Activity: Q1 2021 in Review
33 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q1 2021, worth a combined $617M.
Buyers outnumbered sellers: 33 funds opened new PHVS positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $103M.
- 33 institutional investors held Pharvaris (PHVS) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $617M of Pharvaris stock for Q1 2021.
- 33 funds opened new Pharvaris positions in Q1 2021 and 0 closed out, a net change of +33 holders.
- The largest Pharvaris buyer in Q1 2021 was Foresite Capital Management IV, an estimated $103M added.
Based on aggregated 13F filings for Q1 2021.